ROCKWELL MEDICAL, INC.

Rockwell Medical, Inc. received a notice from Nasdaq on May 8, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company's common stock traded below $1.00 for 30 consecutive business days. Rockwell Medical has 180 calendar days, until November 4, 2026, to regain compliance. The company plans to propose a reverse stock split to its stockholders to address this issue.

Rockwell Medical, Inc. announced on May 7, 2026, that it has made available an updated corporate presentation. This presentation is furnished as Exhibit 99.1 to the Form 8-K filing, providing stakeholders with the latest company information.

Rockwell Medical reported a decrease in net sales and an increase in net loss for the first quarter of 2026 compared to the same period in 2025. Net sales fell by 8.3% to $17.3 million, while net loss grew to $1.6 million. Despite these financial declines, the company improved its net cash used in operating activities and maintains $23.9 million in cash, cash equivalents, and available-for-sale investments, with management believing it has sufficient funds for the next twelve months. However, a significant customer, DaVita, plans to transition to another supplier, although their agreement has been extended through December 2026.

Rockwell Medical announced its first quarter 2026 financial results, reporting $17.3 million in net sales, an 8% decrease year-over-year, and a net loss of $1.6 million. Despite the sales decline, gross margin slightly improved to 17%. The company also provided updated 2026 guidance, emphasizing growth, improved gross margin, and generating positive cash flow, driven by operational changes expected to yield over $3 million in additional annualized gross profit and over $2 million in annualized savings.

Rockwell Medical, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 12, 2026. Key proposals include the election of two Class II directors, an advisory vote on executive compensation, and the ratification of EisnerAmper LLP as the independent auditor. The company also seeks approval for an amendment to its Certificate of Incorporation to effect a reverse stock split of its common stock.